Cite
HARVARD Citation
Javle, M. et al. (2021). Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet oncology. 22 (9), pp. 1290-1300. [Online].